Wockhardt launches Indian injections in the US

Mumbai, Dec 27: Wockhardt USA Inc., Wockhardt's US subsidiary, today announced that they have launched the Ondansetron injection, which is manufactured in India and is used for controlling nausea and vomiting following cancer chemotherapy, in the United States, the first working day after the patent for the product expired on December 24.

''This is Wockhardt's eighth product approval from US Food and Drug Administration (FDA) this year and the third injection product in the US market. We now market 15 products in the US, 10 of which were launched this year itself,'' Wockhard chairman Mr Habil Khorakiwala said in a statment.

Ondansetron is the generic version of Glaxo SmithKline's Zofran injection .

It is pertinent to note here that the Ondansetron injection is manufactured at the US FDA certified sterile formulation plant at Waluj in Aurangabad district. Besides, Wockhardt also has two other sterile formulation plants approved by US FDA in India and the UK.

Wockhardt's new drug discovery programme has yielded several promising molecules, one of which is now in Phase II human clinical trials, it's release added.

UNI